Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations

Marisa C Liu MD, MPH, Krishnansu S Tewari MD

Abstract

Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.

Article Details

Article Type

Review

DOI

10.7573/dic.212558

Publication Dates

Accepted: ; Published: .

Citation

Liu MC, Tewari KS. Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. Drugs in Context 2018; 7: 212558. DOI: 10.7573/dic.212558

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.